Baxter was granted FDA 510(k) clearance to market ALTAPORE Bioactive Bone Graft as an autograft extender in posterolateral spinal fusion, adding to its previous indication for use in the extremities and pelvis. Launch is expected by year-end.
In a pre-clinical fusion model, ALTAPORE as an autograft extender exhibited similar fusion rates to iliac crest autograft, the current standard of care.
Baxter was granted FDA 510(k) clearance to market ALTAPORE Bioactive Bone Graft as an autograft extender in posterolateral spinal fusion, adding to its previous indication for use in the extremities and pelvis. Launch is expected by year-end.
In a pre-clinical fusion model, ALTAPORE as an...
Baxter was granted FDA 510(k) clearance to market ALTAPORE Bioactive Bone Graft as an autograft extender in posterolateral spinal fusion, adding to its previous indication for use in the extremities and pelvis. Launch is expected by year-end.
In a pre-clinical fusion model, ALTAPORE as an autograft extender exhibited similar fusion rates to iliac crest autograft, the current standard of care.
Copy to clipboard 
